All Drugs and Chemicals

Antineoplastic Agents

Amino Acids

Antibodies

Antibodies, Monoclonal

Pembrolizumab

Nivolumab

Ipilimumab

Immunoglobulins

Antibodies, Blocking

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Tyrosine

The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.

Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.

Sitravatinib

Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody

Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)

Enfortumab Vedotin-Ejfv

Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody

Ronald Shazer, MD

A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies

Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that inhibits several closely related RTKs including the TAM family (Tyro3/Axl/MERTK), VEGFR2, KIT, and MET.

The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies

Frequency of subjects experiencing treatment-related AEs.

Time to clinical or radiographic progression on study.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study	NCT04887870	Advanced or Met...	Sitravatinib Nivolumab Pembrolizumab Enfortumab Vedo... Ipilimumab	18 Years -	Mirati Therapeutics Inc.
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study	NCT04887870	Advanced or Met...	Sitravatinib Nivolumab Pembrolizumab Enfortumab Vedo... Ipilimumab	18 Years -	Mirati Therapeutics Inc.

Spots Global Cancer Trial Database for advanced or metastatic solid malignancies